Q-Check Pharmaceuticals — Care beyond Healthcare

Orthopedics Shifting from Damage Control to Tissue Regeneration

Joint replacement surgery represents the endpoint of a long degenerative process. The emerging paradigm in orthopedics — driven by regenerative medicine — seeks to interrupt that process earlier, repairing and regenerating tissue rather than replacing it.

Mesenchymal Stem Cell Therapy: Cartilage Regeneration in Practice

Phase 2–3 clinical trials of mesenchymal stem cell (MSC) therapy for osteoarthritis are demonstrating cartilage regeneration that was previously considered impossible. The results are clinically significant: 60–70% of treated patients avoid joint replacement at 2-year follow-up.

PRP: The Evolution Toward Higher-Efficacy Preparations

Platelet-rich plasma (PRP) therapy has matured significantly. Newer high-concentration, activated preparations demonstrate superior efficacy, with Level 1 evidence now established for mild-to-moderate osteoarthritis. Cost differential: ₹15,000–25,000 per PRP injection versus ₹500,000+ for joint replacement.

Exosome Therapy: The Next Generation

Cell-free regenerative medicine using exosomes is the 2025–2026 frontier. Preliminary data shows similar efficacy to stem cells with a better safety profile and simpler administration.

Imaging-Guided Injection: Precision Delivery

Real-time ultrasound-guided injection placement achieves 95% accuracy in cartilage penetration versus 60% with blind injection.

Research Sources